Location of Repository

Pre Clinical and Clinical Studies of the Effects of Resveratrol, a Phytochemical With Potential Chemopreventive Efficacy

By Victoria Alison Brown


Resveratrol, found in grape skins and red wine, has potential chemopreventive activity in vitro at concentrations ≥5μM. This project explored the tolerability, pharmacokinetics and pharmacodynamics of resveratrol in two clinical phase 1 studies. In vivo data were supported by in vitro studies designed to mimic the daily dosing protocol, using concentrations observed clinically. Forty healthy volunteers received 29 oral daily doses of 0.5, 1.0, 2.5 and 5.0g resveratrol and 20 colorectal cancer patients 8 oral daily doses of 0.5 and 1.0g prior to surgical resection. The pharmacodynamics of resveratrol were assessed by measuring changes in plasma levels of proteins involved in the IGF system, oxidative DNA damage in whole blood and colorectal tissue (M1dG), effects on inflammatory pathways in plasma (PGE2) and colorectal tissue (COX-2), as well as colorectal tissue proliferation (Ki-67). \ud No serious adverse events were reported. In volunteers, mean peak plasma levels of resveratrol across the dose groups ranged from 44.7-954ng/mL (0.20-4.20μM), and for the main metabolite, resveratrol-3-sulfate, were 4-13 fold-higher. Despite low systemic bioavailability, resveratrol concentrations associated with potential chemopreventive efficacy were observed in colorectal tumour tissue with a mean of 44.0nmol/g detected in patients receiving the 1.0g dose (range 0.30-195nmol/g). \ud Post dosing, IGF-1 levels were reduced by 8% (P=0.03) in volunteers and by 33% (P<0.001) in colorectal cancer patients. In tissue, a reduction in cell proliferation of 5.5% (P=0.05) was observed, whilst there was an increase in COX-2 staining (P=0.004). Apart from the 2.5g dose in volunteers, where a significant increase was observed in blood M1dG (21.6%, P=0.02), resveratrol did not significantly affect plasma PGE2 or markers of DNA damage in either study. In cultured colon cancer cells, daily exposure to resveratrol was associated with increased antiproliferative activity compared to an equivalent single dose, supporting the indication that chronic administration may cause pharmacodynamic changes in humans. The work presented here suggests resveratrol has potential as a cancer chemopreventive agent and controlled clinical trials are now warranted

Publisher: University of Leicester
Year: 2010
OAI identifier: oai:lra.le.ac.uk:2381/8203

Suggested articles



  1. (2005). A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.
  2. (1990). A genetic model for colorectal tumorigenesis.
  3. (2008). A novel function of red wine polyphenols in humans: Prevention of absorption of cytotoxic lipid peroxidation products.
  4. (2003). A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.
  5. (1987). A proposal for the standardization of the immunoreactive score (IRS) for the immunohistochemical demonstration of estrogen-receptors (ER-ICA) in breast-cancer.
  6. (2004). A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily.
  7. (2000). A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.
  8. (1988). A protective effect of sulindac against chemically-induced primary colonic tumors in mice.
  9. (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
  10. (2003). A randomized trial of aspirin to prevent colorectal adenomas.
  11. (2003). A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
  12. (2006). A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
  13. (2003). A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in Familial Adenomatous Polyposis patients.
  14. (2001). A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol.
  15. (1997). A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells.
  16. (2003). A unified model for apical caspase activation.
  17. (2003). Absorption of three wine-related polyphenols in three different matrices by healthy subjects.
  18. (2001). Absorption of trans-resveratrol in rats. Flavonoids and other polyphenols.
  19. (2007). Abstract during PhD registration period – unrelated to the PhD research presented in this thesis
  20. (2001). Acromegaly and cancer: A problem.
  21. (1995). Administration of wine and grape juice inhibits in-vivo platelet activity and thrombosis in stenosed canine coronary-arteries.
  22. (2007). Akt/pkb signaling: Navigating downstream.
  23. (1999). Altered expression of the IGF-I receptor in a tamoxifen-resistant human breast cancer cell line.
  24. (2000). Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells.
  25. (1995). Antioxidant action of resveratrol in lipid-peroxidation.
  26. (2000). Antioxidative and prooxidative action of stilbene derivatives.
  27. (2009). Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review.
  28. (2002). Apoptosis: A link between cancer genetics and chemotherapy.
  29. (2007). Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
  30. (1995). Aspirin and the risk of colorectal cancer in women.
  31. (2008). Aspirin dose and duration of use and risk of colorectal cancer in men.
  32. (2004). Aspirin, nsaids, and colorectal cancer: Possible involvement in an insulin-related pathway.
  33. (2000). Assessment of resveratrol bioavailability in the perfused small intestine of the rat.
  34. (1989). Bcl-2-immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation.
  35. (2009). Beta-carotene affects oxidative stress related DNA damage in lung epithelial cells and in ferret lung.
  36. (2005). BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.
  37. (2002). Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane.
  38. (2005). Bioactivity and metabolism of trans-resveratrol orally administered to wistar rats.
  39. (2005). Bioavailability of trans-resveratrol from red wine in humans.
  40. (1998). Biologic activity of tamoxifen at low doses in healthy women.
  41. (2004). Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: An update prologue.
  42. (2000). Blocking and suppressing mechanisms of chemoprevention by dietary constituents. Toxicology Letters (Shannon),
  43. (2002). Breast cancer chemoprevention: Risk-benefit effects of the antioestrogen tamoxifen.
  44. (2006). C-Myc downregulation: A critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells.
  45. (2000). Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: A randomised intervention trial.
  46. (2000). Cancer biology,
  47. (1993). Cancer chemoprevention - principles and prospects.
  48. (2003). Cancer chemoprevention with dietary phytochemicals.
  49. (2008). Cancer chemoprevention: A radical perspective.
  50. (1994). Cancer chemoprevention.
  51. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.
  52. (2002). Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol.
  53. (2008). Cancer prevention: Chemoprevention.
  54. (2006). Cancer statistics,
  55. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
  56. (2008). Cardiovascular events associated with rofecoxib: Final analysis of the APPROVe trial.
  57. (2006). Celecoxib for the prevention of sporadic colorectal adenomas.
  58. (2001). Cell cycle dysregulation and apoptosis of human epidermoid carcinoma A431 cells by trans-resveratrol.
  59. (1999). Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials.
  60. (2005). Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the apical membrane of human intestinal Caco-2 cells.
  61. (1989). Checkpoints - controls that ensure the order of cell-cycle events.
  62. (2007). Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential.
  63. (1999). Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism.
  64. (1985). Chemoprevention of cancer.
  65. (2005). Chemoprevention of colorectal cancer; the role of COX-2 inhibitors, from the bench to the bed-side.
  66. (2000). Chemoprevention of colorectal cancer.
  67. (2000). Chemoprevention of Familial Adenomatous Polyposis development in the APC Min mouse model by 1,4-phenylene bis(methylene)selenocyanate.
  68. (1998). Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli min mouse model with aspirin.
  69. (2005). Chemoprevention: A primary cancer prevention strategy.
  70. (2005). Chemoprevention: From research to clinical oncology.
  71. (1998). Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells.
  72. (2007). Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells.
  73. (2006). Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis.
  74. (2000). Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB Kinase.
  75. (2004). Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol.
  76. (1998). Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.
  77. (2002). Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis.
  78. (1998). Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.
  79. (2006). Clinical Cancer Advances 2005: Major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology.
  80. (1984). Cloning of the chromosome breakpoint of neoplastic B cells with the t(14-18) chromosome-translocation.
  81. (2005). Colorectal cancer prevention.
  82. (1995). Colorectal-cancer and estrogen replacement therapy - a metaanalysis of epidemiologic studies.
  83. (1988). Colorectal-cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study.
  84. (1997). Comparative study of radical scavenger and antioxidant properties of phenolic compounds from vitis vinifera cell cultures using in vitro tests.
  85. (2005). Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4 '-tetramethoxystilbene (DMU-212) on adenoma development in the APC Min mouse and cyclooxygenase-2 in human-derived colon cancer cells.
  86. (1995). Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation.
  87. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression.
  88. (2004). Crystal structure of quinone reductase 2 in complex with resveratrol.
  89. (1996). Cyclin-dependent kinase 7: At the cross-roads of transcription, DNA repair and cell cycle control?
  90. (1997). Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage.
  91. (1996). Cyclo-oxygenase-2 messenger rna induction in focal cerebral ischemia.
  92. (2004). Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.
  93. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells.
  94. (2005). Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention.
  95. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor.
  96. (2005). Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels.
  97. (2002). Death and anti-death: Tumour resistance to apoptosis.
  98. (2002). Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis.
  99. (2001). Design considerations for efficient prostate cancer chemoprevention trials.
  100. (1999). Determination of trans-resveratrol in plasma by HPLC.
  101. (2005). Development of cancer chemopreventive drugs based on mechanistic approaches. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis,
  102. (2005). Dietary cancer-chemopreventive compounds: From signaling and gene expression to pharmacological effects.
  103. (1999). Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults.
  104. (2005). Dietary polyphenols and the prevention of diseases.
  105. (2004). Dietary resveratrol does not affect intestinal tumorigenesis in APC Min mice.
  106. (2006). Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development.
  107. (2003). Differential expression of genes induced by resveratrol in LNCAP cells: P53-mediated molecular targets.
  108. (2007). Direct in vivo evidence of protective effects of grape seed procyanidin fractions and other antioxidants against ethanol-induced oxidative DNA damage in mouse brain cells.
  109. (2002). Disruption of dihydronicotinamide riboside: Quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity.
  110. (2003). Distribution of [ C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration.
  111. (1987). Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development.
  112. (2001). Downregulation of the cyclin D1/CDK4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines.
  113. (1998). Drugs and colon cancer.
  114. (1994). Effect of a null mutation of the insulin-like growth-factor-I receptor gene on growth and transformation of mouse embryo fibroblasts.
  115. (1998). Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-1 serum levels in women with breast cancer.
  116. (1994). Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine.
  117. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies.
  118. (2008). Effect of food on the pharmacokinetic profile of trans-resveratrol.
  119. (2003). Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer.
  120. (2006). Effect of resveratrol on proliferation and telomerase activity of human colon cancer cells in vitro.
  121. (2000). Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production.
  122. (2009). Effect of selenium and vitamin e on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).
  123. (1999). Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women.
  124. (1990). Effect of tamoxifen on serum insulin-like growth factor-I levels in stage-I breast-cancer patients.
  125. (1989). Effect of wheat fiber and vitamin C and E on rectal polyps in patients with Familial Adenomatous Polyposis.
  126. (2003). Effects of 3 days of 'postoperative' low caloric feeding with or without bed rest on insulin sensitivity in healthy subjects.
  127. (2005). Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers.
  128. (1996). Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.
  129. (1992). Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis.
  130. (1991). Effects of long-term sulindac therapy on colonic polyposis.
  131. (2003). Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes.
  132. (2000). Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: Evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action.
  133. (2003). Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma -evidence for cox-2 induction by areca quid ingredients in oral keratinocytes.
  134. (1993). Endothelium-dependent vasorelaxing activity of wine and other grape products.
  135. (1986). Enhanced levels of insulin-like growth-factor messenger-RNA in human-colon carcinomas and liposarcomas.
  136. (2003). Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule.
  137. (2007). Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors.
  138. (1998). Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats.
  139. (1994). Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium.
  140. (2001). Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
  141. (1999). Expression of cyclooxygenase-2 mRNA after global ischemia is regulated by AMPA receptors and glucocorticoids.
  142. (1999). Expression of insulin-like growth factor-1 receptor in human colorectal cancer.
  143. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial.
  144. (1996). Free radicals and surgical stress.
  145. (2006). Free radicals, metals and antioxidants in oxidative stress-induced cancer.
  146. (2003). Genomic medicine - hereditary colorectal cancer.
  147. (1999). Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo [4,5-b]pyridine by human microsomal UDP-glucuronosyltransferases: Identification of specific UGT1A family isoforms involved.
  148. (2000). Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver.
  149. (2006). Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms.
  150. (2003). Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells.
  151. (2004). Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3.
  152. (2004). High absorption but very low bioavailability of oral resveratrol in humans.
  153. (2005). How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men.
  154. (2004). Human hepatic cell uptake of resveratrol: Involvement of both passive diffusion and carrier-mediated process.
  155. (2006). Human sulfotransferases and their role in chemical metabolism.
  156. (2002). Human, rat, and mouse metabolism of resveratrol.
  157. (1996). Hydroxylated stilbenes in selected American wines.
  158. (2001). IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: Association with colorectal cancer in a cohort of Chinese men in Shanghai.
  159. (2007). Impact of physiological, and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.
  160. (2002). Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis.
  161. (2006). In vivo oxidative metabolism of a major peroxidation-derived DNA adduct,
  162. (2003). Increasing the throughput and productivity of Caco-2 cell permeability assays using liquid chromatography-mass spectrometry: Application to resveratrol absorption and metabolism.
  163. (1980). Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors.
  164. (1997). Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression.
  165. (1996). Induction of cyclooxygenase-2 mRNA in gerbil hippocampal neurons after transient forebrain ischemia.
  166. (2007). Inflammation and cancer: An ancient link with novel potentials.
  167. (1999). Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol.
  168. (2002). Inhibition of cancer growth by resveratrol is related to its low bioavailability.
  169. (2007). Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.
  170. (2001). Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components.
  171. (1981). Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment.
  172. (2003). Inhibition of free radical-induced peroxidation of rat liver microsomes by resveratrol and its analogues. Biochimica Et Biophysica Acta-Molecular Basis of Disease,
  173. (1997). Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
  174. (1993). Inhibition of oxidation of human low-density-lipoprotein by phenolic substances in red wine.
  175. (1999). Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production.
  176. (2007). Ins and outs of dietary phytochemicals in cancer chemoprevention.
  177. (1998). Insulin and related factors in premenopausal breast cancer risk.
  178. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis.
  179. (2002). Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
  180. (2004). Insulin-like growth factor-I and cancer risk.
  181. (2005). Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps.
  182. (1986). Insulin-like growth factor-I receptor primary structure -comparison with insulin-receptor suggests structural determinants that define functional specificity.
  183. (1995). Insulin-like growth-factor-I receptor - its role in cell-proliferation, apoptosis, and tumorigenicity.
  184. (1993). Insulin-like growth-factors and binding-proteins in colon-cancer.
  185. (2002). Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer.
  186. (2001). Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance.
  187. (1998). Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen Randomised Chemoprevention Trial. The Lancet,
  188. (1997). Investigations of mitochondrial DNA point mutations and mitochondrial oxidants in aging and disease.
  189. (2002). Involvement of c-jun NH2-terminal kinases in resveratrol-induced activation of p53 and apoptosis.
  190. (2001). Involvement of the retinoblastoma (pRb)-E2F/DP pathway during anti proliferative effects of resveratrol in human epidermoid carcinoma (A431) cells.
  191. (2007). Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk.
  192. (1992). Ki-67 labeling index and survival of the patients with colorectal carcinoma.
  193. (1998). Kinetic analysis of copper-induced peroxidation of LDL.
  194. (2000). Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas.
  195. (1999). Lipid peroxidation - DNA damage by malondialdehyde.
  196. (2006). Liquid chromatography-electrospray ionization-mass spectrometry: The future of DNA adduct detection.
  197. (2003). Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.
  198. (2001). Lobe-specific increases in malondialdehyde DNA adduct formation in the livers of mice following infection with helicobacter hepaticus.
  199. (2007). Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial.
  200. (2005). Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.
  201. (2004). Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor.
  202. (1993). Low-dose aspirin and incidence of colorectal tumors in a randomized trial.
  203. (2005). Low-dose aspirin in the primary prevention of cancer the Women's Health Study: A randomized controlled trial.
  204. (2007). Lycopene supplementation elevates circulating insulin-like growth factor-binding protein-1 and-2 concentrations in persons at greater risk of colorectal cancer.
  205. (1987). Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues.
  206. (2007). Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines.
  207. (2005). Metabolism and bioavailability of trans-resveratrol.
  208. (2002). Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model.
  209. (2008). Metabolism of resveratrol in breast cancer cell lines: Impact of sulfotransferase 1A1 expression on cell growth inhibition.
  210. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
  211. (2006). Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis.
  212. (1999). Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5.
  213. (1999). Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis,
  214. (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis,
  215. (2003). Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction.
  216. (1996). Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women.
  217. (1998). Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma.
  218. (2002). Nutrition, energy balance and colon cancer risk: The role of insulin and insulin-like growth factor-I.
  219. (2000). Obesity: Preventing and managing the global epidemic. Report of a WHO consultation.
  220. (2003). Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity.
  221. (2005). Overview of mechanisms of cancer chemopreventive agents. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis,
  222. (2003). Overview of the main outcomes in breast-cancer prevention trials.
  223. (2003). Oxidative DNA damage: Mechanisms, mutation, and disease.
  224. (2000). Oxyradicals and DNA damage.
  225. (2002). Oxyresveratrol and hydroxystilbene compounds - inhibitory effect on tyrosinase and mechanism of action.
  226. (2001). P21 WAF1/CIP1 is an important determinant of intestinal cell response to sulindac in vitro and in vivo.
  227. (2007). P53 in health and disease.
  228. (1997). Participation in colorectal cancer screening: A review.
  229. (2003). Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.
  230. (2009). Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.
  231. (2004). Pharmacokinetics and metabolism of dietary flavonoids in humans.
  232. (2004). Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4 '-tetramethoxystilbene.
  233. (2006). Pharmacokinetics of selected stilbenes: Rhapontigenin, piceatannol and pinosylvin in rats.
  234. (2002). Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: Formation of different metabolites and individual variability.
  235. (2008). Pharmacometrics of pterostilbene: Preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity.
  236. (2007). Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.
  237. (2008). Phase I repeat-dose clinical study of safety, pharmacokinetics and pharmacodynamics of resveratrol. The American Association of Cancer Research Meeting Abstracts,
  238. (2005). Phase I study of green tea extract in patients with advanced lung cancer.
  239. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats.
  240. Phosphorylation of c-Jun and its localization with heme oxygenase-1 and cyclooxygenase-2 in CA1 pyramidal neurons after transient forebrain ischemia.
  241. (2002). Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines.
  242. (2002). Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: A prospective study in northern Sweden.
  243. (1998). Plasma metabolites of quercetin and their antioxidant properties.
  244. (1996). Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats.
  245. (2002). Plasmatic levels of trans-resveratrol in rats.
  246. (2004). Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: Protection against oxidative and electrophilic injury.
  247. (1976). Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proceedings,
  248. (2003). Prevention of prostate cancer with finasteride: US/European perspective.
  249. (2002). Primary chemoprevention of Familial Adenomatous Polyposis with sulindac.
  250. (2005). Principles and practice of oncology 8ed.: Lippincott Williams
  251. (1976). Production of resveratrol by vitis-vinifera and other members of vitaceae as a response to infection or injury.
  252. Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials.
  253. (1993). Proliferation and differentiation biomarkers in colorectal mucosa and their application to chemoprevention studies.
  254. (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.
  255. (2008). Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides -two novel resveratrol metabolites in human plasma.
  256. (2005). Quantitation and detection of trans-resveratrol, a potential cancer chemopreventive agent, and its metabolites in human plasma and urine by high performance liquid chromatography.
  257. (2007). Quantitation of Silibinin, a Putative Cancer Chemopreventive Agent Derived from Milk Thistle (Silybum marianum), in Human Plasma by High-Performance Liquid Chromatography and Identification of Possible Metabolites.
  258. (2002). Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway.
  259. (2000). Radioimmunological measurement of F2-isoprostanes after hydrolysis of lipids in tissues.
  260. (1996). Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
  261. (1996). Randomised study of screening for colorectal cancer with faecal-occult-blood test.
  262. Randomized trial of intake of fat, fiber, and beta-carotene to prevent colorectal adenomas.
  263. (2004). Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells.
  264. (2003). Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.
  265. (2001). Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.
  266. (2001). Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.
  267. (2001). Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human.
  268. (2003). Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum.
  269. (2003). Resveratrol activates adenylyl-cyclase in human breast cancer cells: A novel, estrogen receptor-independent cytostatic mechanism.
  270. (2002). Resveratrol affects in a different way primary versus fixed DNA damage induced by H2O2 in mammalian cells in vitro.
  271. (2001). Resveratrol analog, 3,5,2 ',4 '-tetramethoxy-trans-stilbene, potentiates the inhibition of cell growth and induces apoptosis in human cancer cells.
  272. (2008). Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutation Research-Reviews in Mutation Research,
  273. (2005). Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises.
  274. (2008). Resveratrol as an inhibitor of carcinogenesis.
  275. (1998). Resveratrol blocks eicosanoid production and chemically-induced cellular transformation: Implications for cancer chemoprevention.
  276. (2003). Resveratrol blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.
  277. (2001). Resveratrol causes WAF-l/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
  278. (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.
  279. (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting Bax and p21 CIP expression.
  280. (2007). Resveratrol enhances insulin secretion by blocking KATP and KV channels of beta cells.
  281. (2005). Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor.
  282. (2006). Resveratrol improves health and survival of mice on a high-calorie diet.
  283. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α.
  284. (2007). Resveratrol in human hepatoma hepg2 cells: Metabolism and inducibility of detoxifying enzymes.
  285. (2006). Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo.
  286. (2001). Resveratrol induces colon tumor cell apoptosis independently of p53 and preceded by epithelial differentiation, mitochondrial proliferation and membrane potential collapse.
  287. (2000). Resveratrol inhibition of lipid peroxidation.
  288. (1998). Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells.
  289. (2006). Resveratrol inhibits insulin secretion from rat pancreatic islets.
  290. (2001). Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human Familial Adenomatous Polyposis.
  291. (2006). Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity.
  292. (1999). Resveratrol is a selective human cytochrome P450 1A1 inhibitor.
  293. (2000). Resveratrol is absorbed in the small intestine as resveratrol glucuronide.
  294. (2006). Resveratrol is rapidly metabolized in athymic (Nu/Nu) mice and does not inhibit human melanoma xenograft tumor growth.
  295. (2006). Resveratrol modulation of signal transduction in apoptosis and cell survival: A mini-review. Cancer Detection and Prevention,
  296. (2003). Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses.
  297. (1999). Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway.
  298. (2007). Resveratrol suppresses prostate cancer progression in transgenic mice.
  299. (2000). Resveratrol suppresses TNF-induced activation of nuclear transcription factors NFκB, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation.
  300. (2003). Resveratrol transport and metabolism by human intestinal Caco-2 cells.
  301. (2004). Resveratrol-associated renal toxicity.
  302. (2007). Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells.
  303. (2003). Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells.
  304. (2003). Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene.
  305. (2001). Resveratrol, a natural chemopreventive agent against degenerative diseases.
  306. (2001). Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutation Research-Genetic Toxicology and Environmental Mutagenesis,
  307. (2006). Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats.
  308. (2000). Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.
  309. (1999). Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells.
  310. (2007). Resveratrol: A review of preclinical studies for human cancer prevention.
  311. (2009). Resveratrol: Cellular actions of a potent natural chemical that confers a diversity of health benefits.
  312. (1996). Resveratrol: Isomeric molar absorptivities and stability.
  313. (1999). Resvesatrol increases nitric oxide synthase, induces accumulation of p53 and p21 WAF1/CIP1 and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2.
  314. (2004). Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials.
  315. (2002). Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells.
  316. (1990). Role of insulin-like growth-factors and the type-i insulin-like growth-factor receptor in the estrogen-stimulated proliferation of human breast-cancer cells.
  317. (2004). Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies.
  318. (2000). Role of the insulin-like growth factor family in cancer development and progression.
  319. (1999). Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction.
  320. (2009). Safety studies conducted on high-purity trans-resveratrol in experimental animals.
  321. (2004). Sensitization for tumor necrosis factor-related apoptosis-inducing ligand induced apoptosis by the chemopreventive agent resveratrol.
  322. (2000). Serum insulin-like growth factor-I and breast cancer.
  323. (1993). Serum lipoperoxide levels in surgical stress of abdominal hysterectomy.
  324. (2005). Signal transduction network leading to COX-2 induction: A road map in search of cancer chemopreventives.
  325. (2000). Signal transduction pathways: Targets for chemoprevention of skin cancer.
  326. (2005). Signaling and interplay mediated by phospholipases
  327. (2006). SIRT1, neuronal cell survival and the insulin/IGF-1 aging paradox.
  328. (1997). Site of insulin resistance after surgery: The contribution of hypocaloric nutrition and bed rest.
  329. (2003). Small molecule activators of sirtuins extend saccharomyces cerevisiae lifespan.
  330. (1997). Somatic frameshift mutations in the Bax gene in colon cancers of the microsatellite mutator phenotype.
  331. (1995). Stimulation of rat hepatic UDP-glucuronosyl transferase activity following treatment with green tea.
  332. (2000). Structure and function of the type 1 insulin-like growth factor receptor. Cellular and Molecular Life Sciences,
  333. (2008). Structure, function and polymorphism of human cytosolic sulfotransferases.
  334. (1975). Studies of the enterohepatic circulation of morphine in the rat.
  335. (2005). Sulfation of resveratrol in human liver: Evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1.
  336. (2008). Sulfotransferase gene copy number variation: Pharmacogenetics and function.
  337. (1991). Sulindac causes regression of rectal polyps in Familial Adenomatous Polyposis.
  338. (2000). Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids.
  339. (2000). Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum.
  340. (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-κB, cyclooxygenase 2, and matrix metalloprotease 9.
  341. (2002). Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol.
  342. (1999). Surgical stress and the small intestine: Role of oxygen free radicals.
  343. (1997). Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
  344. (2002). Surveillance guidelines after removal of colorectal adenomatous polyps.
  345. (2006). Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
  346. (2003). Survivin in apoptosis control and cell cycle regulation in cancer.
  347. (2002). Tamoxifen for breast cancer among hysterectomised women.
  348. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
  349. (1997). Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.
  350. (2006). The apoptosome activates caspase-9 by dimerization.
  351. (1997). The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases.
  352. The Calcium Polyp Prevention Study Group 1999. Calcium supplements for the prevention of colorectal adenomas.
  353. (2002). The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYPIBI.
  354. (1999). The central effectors of cell death in the immune system.
  355. (2005). The chemopreventive agent resveratrol stimulates cyclic AMP - dependent chloride secretion in vitro.
  356. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in Familial Adenomatous Polyposis. New England
  357. (2000). The effect of fecal occult-blood screening on the incidence of colorectal cancer.
  358. (1995). The effects of sulindac on colorectal proliferation and apoptosis in Familial Adenomatous Polyposis.
  359. (2005). The emperor wears no clothes in the field of carcinogen risk assessment: Ignored concepts in cancer risk assessment.
  360. (1999). The IGF axis and programmed cell death.
  361. (2003). The IGF-1 receptor in cancer biology.
  362. (1997). The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis.
  363. (2004). The models for assessment of chemopreventive agents: Single organ models.
  364. (1996). The nutritional prevention of cancer with selenium: A randomized trial.
  365. (1991). The production of resveratrol (3,5,4'-trihydroxystilbene) by grape berries in different developmental stages.
  366. (2003). The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
  367. (1999). The relationship between cyclooxygenase-2 expression and colorectal cancer.
  368. (1999). The role of cyclooxygenases in inflammation, cancer, and development.
  369. (2004). The role of oxidative stress in carcinogenesis.
  370. (2000). The roles of glutathione and antioxidant enzymes in menadione-induced oxidative stress.
  371. (2004). The SIR2 family of protein deacetylases.
  372. (2008). The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.
  373. (1983). The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat.
  374. (2007). The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force.
  375. (2006). Therapeutic potential of resveratrol: The in vivo evidence.
  376. (2001). To cycle or not to cycle: A critical decision in cancer.
  377. (2005). Toxicogenomics of resveratrol in rat liver.
  378. (2007). Toxicokinetics of resveratrol in dogs.
  379. (2000). Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P4501B1.
  380. (2002). Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.
  381. (2002). Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development : Recommendations of the American Association for Cancer Research Task Force on the treatment and prevention of intraepithelial neoplasia.
  382. (1993). Treatment of colonic and rectal adenomas with sulindac in Familial Adenomatous Polyposis. New England
  383. (2008). Understanding pathways of calorie restriction: A way to prevent cancer?
  384. (2004). Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice.
  385. (1990). Validation of intermediate end points in cancer research.
  386. (2002). Vaticanol C, a novel resveratrol tetramer, inhibits cell growth through induction of apoptosis in colon cancer cell lines.
  387. (1997). Wine as a biological fluid: History, production, and role in disease prevention.
  388. (1992). Wine, alcohol, platelets, and the French paradox for coronary heart-disease.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.